Research and Markets: Drivers of M&A in 2013-16: PI3Ks and BTK Inhibitors

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/nlh6ft/drivers_of_manda) has announced the addition of the "Drivers of M&A In 2013-2016: Phosphoinositide 3-Kinases (PI3Ks) And Bruton's Tyrosin Kinase (BTK) Inhibitors" report to their offering.

Targeting kinases have been on the agenda of most drug developers/ researchers as they hold the key path to signaling, development and growth of the cell. Tumors/cancer biology indicates that this balance is disturbed and inhibiting the aberrant pathways in a balanced way is an approach to developing drugs against cancer.

Resistance to existing therapies develops as cancer cells bypass these efforts and their remains an evergreen search for new targets to meet these challenges. Large global pharma are constantly on the hunt for drugs with label expansion potential = Longevity and Blockbuster Potential! About $10b+ has already been invested in licensing /acquisition of PI3K and other kinase inhibitors/companies since the last five years.

Scientific data on the role of PI3K, BTK kinase in cancer and clinical Proof of Concept (PoC) data of the PI3K, BTKs inhibitors have reached a critical mass and companies with focus in this sector are poised to offer better treatment options for unmet need in hematologic malignancies. We expect more acquisitions of the innovator companies and or handsome licensing deals for unpartnered products as mature data and approvals come in the next few years.

This report highlights the recent progress on the understanding of PI3Ks/BTK signaling pathway and companies developing PI3K/BTK inhibitors (PCYC, INFI, CRIS, SymBio, GILD), the clinical data and competition.

KEY POINTS DISCUSSED IN THE REPORT

1. Drugs in the pipeline

PI3K inhibitors – Infinity pharma (INFI), Gilead (GILD)

Dual PI3K inhibitor – Onconova/SymBio, Curis (CRIS)

BTK-inhibitors – Safety and clinical efficacy set it apart – Pharmacyclics (PCYC), Celgene (CELG)

2. M&A in Kinase Inhibitors in the last 5 years

3. Related Milestones/catalysts in 2013-14

4. Combination Studies – PI3K, BTK inhibitors with Rituxan, Bendamustine in hematological cancers.

5. Ongoing Clinical Trials of Companies Covered

6. Detailed Reports on –

- Curis (CRIS) – Time to Assess Value Beyond Erivedge!

- Gilead (GILD) - New HIV + HCV Products to Sustain the Growth Trajectory

- Infinity pharma (INFI) – IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity!

- Pharmacyclics (PCYC) – Ibrutinib - Promising to Deliver More

- SymBio (4582) - Significant Upside still Remains: Bendamustine + Rigosertib + Cash to In-license More!

Companies Mentioned

- SymBio pharma (4582) - recent report + initiation report

- Curis (CRIS) - Initiation report

- Gilead (GILD) - Latest report

- Pharmacyclics (PCYC) - Initiation report

- Infinity pharma (INFI) - Initiation report

- Onconova

- Novartis

- Celgene

- Exelixis/ Sanofi

- Pfizer

For more information visit http://www.researchandmarkets.com/research/nlh6ft/drivers_of_manda

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals